Entities

Xavier Del Rosario is Investment Partner at VamosVentures. He worked at Morgan Stanley and NEA and has operating experience with Bond, Very Good Security and Rightway Healthcare. He holds a Harvard BA.

Sarah Colson is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Erica Glass is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Candice Ellis is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Bailey Mannis is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Maggie Okeowo is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Mary Faith Dudley is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Julie Kieliszak is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Jenny Perez is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Kelly Cesary is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Heather Ferrell is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Judy Ko is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Alexa Belonick is listed in Gunderson Dettmer’s public professional directory as Partner, based in San Francisco. Their published biography describes work involving technology companies, life sciences, corporate governance, securities and public offerings.

Elisabeth M. Bernabe is listed in Gunderson Dettmer’s public professional directory as Associate, based in San Diego.

Joe Berklund is listed in Gunderson Dettmer’s public professional directory as Partner, based in Atlanta. Their published biography describes work involving venture capital, private investment funds.

Nicole Trocchia is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Sasha Benincasa is listed in Gunderson Dettmer’s public professional directory as Associate, based in New York. Their published biography describes work involving venture capital, private investment funds, corporate governance.

Traci A. Biedermann is listed in Gunderson Dettmer’s public professional directory as Associate, based in San Diego. Their published biography describes work involving technology companies, life sciences, corporate governance, securities and public offerings.

Alexis C. Bello is listed in Gunderson Dettmer’s public professional directory as Associate, based in New York. Their published biography describes work involving technology companies, licensing and intellectual property.

Chase N. Beckstead is listed in Gunderson Dettmer’s public professional directory as Associate, based in San Francisco.

David I. Behrend is listed in Gunderson Dettmer’s public professional directory as Associate, based in Silicon Valley.

Derek Richardson is listed in Thyme Care’s public medical-provider directory as Family Physician. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Julie Bateman is listed in Gunderson Dettmer’s public professional directory as Associate, based in Boston. Their published biography describes work involving technology companies, life sciences, licensing and intellectual property, data privacy.

Rafael Bellaver is listed in Gunderson Dettmer’s public professional directory as Associate, based in New York and São Paulo. Their published biography describes work involving venture capital, mergers and acquisitions, securities and public offerings.

Steven L. Baglio is listed in Gunderson Dettmer’s public professional directory as Partner, based in New York. Their published biography describes work involving venture capital, corporate governance, mergers and acquisitions, securities and public offerings.

Tatiana Becker is listed in Gunderson Dettmer’s public professional directory as Associate, based in Boston. Their published biography describes work involving venture capital, private investment funds, corporate governance.

Amber Piriano is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Radiah Nixon is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Kaitlyn Moore is listed in Thyme Care’s public medical-provider directory as Nurse Practitioner. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Asma Dilawari is listed in Thyme Care’s public medical-provider directory as Medical Director of Oncology Care. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Nelia Jain is listed in Thyme Care’s public medical-provider directory as Medical Director of Palliative Care. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Allen A. Amin is listed in Gunderson Dettmer’s public professional directory as Associate, based in Los Angeles. Their published biography describes work involving venture capital, technology companies, mergers and acquisitions.

Amira Abulafi is listed in Gunderson Dettmer’s public professional directory as Associate, based in New York.

Emma Anderson is listed in Gunderson Dettmer’s public professional directory as Associate, based in Austin.

Frida Alim is listed in Gunderson Dettmer’s public professional directory as Associate, based in San Francisco. Their published biography describes work involving venture capital, technology companies, securities and public offerings, data privacy.

Geoff Abbot is listed in Gunderson Dettmer’s public professional directory as Associate, based in New York. Their published biography describes work involving venture capital, private investment funds, corporate governance.

Heather N. Aune is listed in Gunderson Dettmer’s public professional directory as Partner, based in San Diego and Los Angeles. Their published biography describes work involving mergers and acquisitions, employment and talent.

Hilary M. Adams is listed in Gunderson Dettmer’s public professional directory as Partner, based in New York. Their published biography describes work involving venture capital, technology companies.

Remy C. Altman is listed in Gunderson Dettmer’s public professional directory as Associate, based in Boston. Their published biography describes work involving venture capital, private investment funds, corporate governance.

Sahar J. Adora is listed in Gunderson Dettmer’s public professional directory as Associate, based in Ann Arbor.

Scott Armienti is listed in Gunderson Dettmer’s public professional directory as Chief People Officer, based in Silicon Valley.

Sujata Awasthi is listed in Gunderson Dettmer’s public professional directory as Associate, based in Boston and Los Angeles. Their published biography describes work involving venture capital, private investment funds, corporate governance.

Victor L. Arena is listed in Gunderson Dettmer’s public professional directory as Associate, based in New York. Their published biography describes work involving venture capital, technology companies, corporate governance, mergers and acquisitions.

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP is an international law firm serving technology and life-sciences companies and venture and growth investors. Founded in 1995, it advises on company formation, venture financing, mergers and acquisitions, public offerings, fund formation, licensing and data privacy. Its AI and machine-learning practice supports developers and investors, and its innovation team developed ChatGD and the 2025 ChatGD+ legal workflow platform. The current public professional directory lists 386 lawyers and business leaders, including emeritus and advisory affiliations; this is not an exhaustive employee census. Transaction representation alone is not an investment. Separately, Fundamental Research Labs, formerly Altera.AL, explicitly named Gunderson Dettmer as a participant in its January 2024 USD2M preseed financing. No external managed investment fund or closed fund size is verified.

Be My Eyes develops visual-accessibility software for people who are blind or have low vision. Its free consumer app connects users to sighted volunteers and company support agents through live video, while Be My AI describes images and answers visual questions using generative AI. The company also sells accessibility products to businesses, including customer-service tools and Be My Eyes Workplace, which provides screen descriptions, accessible document reading and assistance from trusted colleagues.

Daivergent is a public benefit corporation providing online job-readiness training and life coaching for neurodivergent teens and adults and people with disabilities. Its platform combines technology with live, individual coaching to develop employment, communication and independent-living skills. Programs include REACH Coaching, Future Pathways, work-readiness training and pre-employment transition services for students and schools. The company was founded in 2017 to help neurodivergent job seekers and transition-aged adults prepare for work.

Elice develops AI infrastructure, enterprise AI software and practical technology education platforms. Its Elice Cloud business provides GPU computing, virtualization infrastructure, development environments, model deployment and portable modular AI data centers. Its Helpy software helps organizations analyze documents, structure internal knowledge, use generative AI and deploy coding agents, while Elice LXP and Elice Test support hands-on learning and skills assessment. Based in Seoul and founded in 2015, Elice serves enterprises, public institutions, schools and researchers.

MBD (Medical & Bio Decision) is a South Korean biotechnology company that builds three-dimensional cell-culture and tumor-organoid platforms for precision oncology and drug development. It uses patient-derived cancer cells to assess anticancer drug sensitivity and offers the OncoSensi testing service to help evaluate treatment response. Its Cellvitro, ASFA Spotter and ASFA Scanner products support automated cell culture and drug screening, while its CRO services evaluate drug efficacy and toxicity for pharmaceutical and research partners.

Mathpresso develops QANDA, an AI education and tutoring platform for students and teachers. QANDA uses optical character recognition to read photographed problems and provides step-by-step solutions, personalized learning content and AI tutoring. Its services include live one-to-one QANDA Tutor lessons, institutional learning-management tools, AI-assisted textbook and teaching workflows, and the Cramify study tool. Mathpresso also develops education-specific models such as MathGPT. Founded in Seoul in 2015, the company serves students internationally across multiple languages.

Niron Magnetics develops and manufactures rare-earth-free permanent magnets using iron nitride, providing an alternative to magnets that depend on constrained critical-mineral supply chains. Its Clean Earth Magnet technology combines materials science and scalable manufacturing processes to serve electric motors and generators, industrial automation and robotics, vehicles, audio equipment, aerospace and defense, and datacenter infrastructure. The Minnesota company operates a commercial pilot plant and is building a full-scale magnet manufacturing facility in Sartell.

NobodyWho is a Copenhagen company developing an open-source AI inference engine that runs language models directly on phones, laptops and embedded devices, or on GPU servers controlled by an organisation. Its on-device and on-premises deployments keep prompts and outputs within the customer’s infrastructure and can work offline without per-token API fees. The EUPL-licensed engine supports compact and larger open models through developer SDKs. Its paid Assurance Layer provides deployment, model selection and optimisation, governance, monitoring, support and tools adapted to customer workflows.

Norrsken Evolve is a Stockholm-based pre-seed venture investment platform in the Norrsken ecosystem, developed from Norrsken Accelerator. It backs founders building a more sustainable and resilient Europe across energy, advanced manufacturing, materials, transport, food, healthcare, biotechnology, information security and related technologies. It combines early equity investment with an in-person founder sprint, mentoring and access to an investor and operator network. Its current published team includes investment professionals, a venture partner and platform and operations staff; its large external adviser network is listed separately.

OTI Lumionics develops advanced electronic materials using computational chemistry, machine learning, quantum and quantum-inspired simulations, and pilot-production testing. Its initial commercial focus is OLED display materials, including self-assembly cathode patterning that creates transparent regions for cameras, infrared sensors and facial-recognition systems beneath a display. The Canadian company works with display manufacturers and chemical suppliers to qualify and scale materials for consumer electronics and automotive displays, while developing simulation methods for broader materials discovery.

Sail Biomedicines develops programmable RNA medicines that act directly inside the body. Its platform combines translatable circular Endless RNA with targeted nanoparticles to control the cells reached and the duration of therapeutic protein expression, using AI and high-throughput experiments to help design medicines. Its lead focus is in vivo CAR-T therapy for immune-mediated diseases. Sail was formed in October 2023 through the combination of Senda Biosciences and Laronde, bringing together their RNA-payload and delivery technologies.

Volumez develops data infrastructure software for enterprise AI, database and other data-intensive cloud workloads. Its SaaS platform composes cloud storage and compute into workload-specific infrastructure using controllerless orchestration and direct Linux data paths, aiming to keep CPUs and GPUs supplied with data while providing predictable performance, resiliency and lower operating costs. Its agentic AI platform brings together governed data access, ingestion, metadata and GPU data delivery so enterprises can deploy and operate AI agents in production. The cloud block storage offering supports AI and machine learning, databases, high-performance computing and Kubernetes environments.

ZutaCore develops waterless direct-to-chip liquid cooling for AI and high-performance computing data centers. Its HyperCool system uses a sealed, closed-loop dielectric fluid that boils and condenses to move heat away from CPUs and GPUs, enabling denser computing and heat recovery without water inside servers. Its OmniTherm cold plates support PCIe accelerators, and HyperCool Cloud provides centralized monitoring, control and optimization across racks and sites. The company supplies cooling technology for hyperscalers, AI cloud providers, enterprise data centers and research computing installations.

Vice President of Marketing at ZutaCore, identified in its June 2026 official funding and leadership announcement as its press contact.

Vice President of Finance and Operations at Volumez.

CEO and Executive Chairman of Volumez, which builds enterprise AI data infrastructure and a cloud block storage platform.

Partner, Artiman Ventures. Published on Niron Magnetics’ board of directors.

Human resources adviser to Volumez, listed in its current official management directory as an adviser.

Marketing executive with experience in international growth, brand development, business transformation and marketing operations.

President and Chief Revenue Officer of ZutaCore, leading commercialization of its waterless liquid cooling technology.

Co-founded Daivergent after working in behavioral healthcare as a data scientist, consultant and researcher. Holds a BA from Harvard University and an MS in Epidemiology from Johns Hopkins.

Managing Partner, Anzu Partners. Published on Niron Magnetics’ board of directors.

Managing Partner, Anzu Partners. Published on Niron Magnetics’ board of directors.

Field CTO and operational adviser to Volumez, listed in its current official management directory in an advisory role.

Leads operations across countries and time zones, drawing on experience in call-center management and sales.

Chairman and CEO of ZutaCore, which develops waterless direct-to-chip liquid cooling systems for AI and high-performance computing.

CEO and Chairman of Ooma. Published on Niron Magnetics’ board of directors.

Frank D'Amelio is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Leads talent development at Elice Group. The issuer publishes the full name 국승명; the record-creation name is transliterated only to generate a stable ID and is not an asserted official English alias.

Visually impaired Danish craftsman whose idea for volunteer video assistance led to Be My Eyes.

Co-founder of Mathpresso, as identified in its official QANDA company facts.

Co-founder and CEO of Elice, leading its AI infrastructure, cloud, enterprise AI and education business. Also published as Jae Won Kim and Kim Jae-won.

Former Niron Chief Operations Officer who transitioned in April 2026 to commissioning and ramping up the company’s full-scale Sartell production plant.

Board Member at AMD, Rocket Lab, and Kulicke & Soffa. Published on Niron Magnetics’ board of directors.

Founder and CTO of Volumez, a developer of data infrastructure for enterprise AI and data-intensive cloud workloads.

Co-founder of Mathpresso, also known as Ray Jongheun Lee. Identified as the company representative in QANDA’s current legal footer.

Elice co-founder and CTO working on AI cloud infrastructure, data centers and large-scale GPU networking. Also published as Jungkuk Park.

Former St. Jude Children’s Research Hospital researcher who analyzes customer feedback and market data.

Advanced manufacturing executive appointed to lead Niron’s operational strategy and production scaling in April 2026. Previously Chief Operating Officer at SEPAC and held manufacturing and supply-chain leadership roles at Corning.

Vice President of Product at Volumez, a developer of enterprise AI data infrastructure and cloud storage software.

Chief Product and Technology Officer at ZutaCore, responsible for its direct-to-chip, two-phase cooling platform.

VP of R&D and Tel Aviv General Manager at Volumez, leading engineering and its Israeli research and development organization.

Technical adviser to Volumez, listed in its current official management directory as an adviser.

Previously managed software engineering teams building healthcare and consumer products, with a specialization in data engineering.

Chief People Officer at ZutaCore. Its June 2026 announcement describes experience in organizational transformation and talent strategy at Coro Cybersecurity, Allot, OptimalPlus, National Instruments and Micron.

Chief Operating Officer of ZutaCore. Its June 2026 announcement describes experience scaling technology operations across AI, machine learning, data infrastructure and enterprise systems.

Leads AI research at Elice, including specialized models, enterprise generative AI and applied research.

Chief of Staff at ZutaCore, listed in its current leadership directory and June 2026 leadership announcement.

Works in program development, training and vocational guidance for people with neurological differences. Previously implemented programs at SAP, UP Michigan Works! and SpArc Philadelphia.

Chief Strategy Officer at ZutaCore, as listed in its current official leadership directory.

Co-founder of Mathpresso, as identified in its official QANDA company facts.

Chief Financial Officer at ZutaCore. Its June 2026 announcement describes prior finance leadership at Gilat Satellite Networks, Sony Semiconductor Israel and Coro Cybersecurity.

Co-founder of Mathpresso, developer of the QANDA AI education platform. Also known as Jake Yongjae Lee.

Chief Research and Development Officer at ZutaCore. Its June 2026 announcement describes an engineering leader with more than 20 years of experience, including senior roles at HP.

Pia Leonhard is Head of Finance & Operations (Maternity Leave) at Discovery Ventures. The current firm directory states: Pia Leonhard Head of Finance & Operations (Maternity Leave) DataGuard, Ciao Bella, Zeitgold.

Joel Stead is a director of Stead Impact Ventures. He held sales, marketing and customer service leadership roles during 18 years at Seagate Technology and established the University of Minnesota Carlson School of Management Leadership Lab.

Sandra Hirsch is Executive Assistant at Discovery Ventures. The current firm directory states: Sandra Hirsch Executive Assistant.

Hannes Streeck is Operator in Residence at Discovery Ventures. The current firm directory states: Hannes Streeck Operator in Residence Managing Director - Fiege CEO - Fiege Far East.

Jay Stead is a director of Stead Impact Ventures and an adviser to software and technology businesses. He formerly led Sagebrush Corporation and held executive roles at Reynolds and Reynolds, with philanthropic interests in healthcare, education and innovation.

Sandy Rosenberg is Senior Advisor at Stead Impact Ventures and founder of Discus Ventures, supporting company development and capital strategy. He previously worked in Citigroup investment banking and serves as an executive in residence and adjunct professor at Tufts University’s Gordon Institute.

Aidan Thompson is Chief Commercial Officer of Stead Impact Ventures, advising portfolio companies on market entry, revenue growth and exit preparation. He has healthcare technology executive experience and a doctorate in neuroscience and biomechanics. Aidan Thompson serves on the Board of Directors of MedWatch Technologies, following Stead Impact Ventures’ financing announcement. He is Chief Commercial Officer of Stead Impact Ventures.

Benjamin Schickert is Operating Partner & CFO at Discovery Ventures. The current firm directory states: Benjamin Schickert Operating Partner & CFO Founder - Myos Morgan Stanley, Allianz.

Jacquee Nickerson is Executive Assistant at Stead Impact Ventures, supporting its leadership and portfolio companies. Her background includes administration across legal, engineering, manufacturing and mental health organizations, an MBA and project management certification.

Tobias Weiper is Partner at Discovery Ventures. The current firm directory states: Tobias Weiper Partner Co-Founder - VATION Co-Founder - evopark.

Dana Larson is Chief Marketing Officer of Stead Impact Ventures, supporting portfolio positioning, customer journeys and growth marketing. Her experience spans technology companies, cultural organizations and University of Iowa fundraising campaigns.

Tiffani Shaw is CEO of Stead Impact Ventures. She previously served as Clarivate chief of staff and as executive vice president and COO of the University of Iowa Center for Advancement, following financial and operational leadership roles.

Stefan Jeschonnek is General Partner at Discovery Ventures. The current firm directory states: Stefan Jeschonnek General Partner Co-Founder - Zeitgold Co-Founder - SumUp.

Jan Deepen is General Partner at Discovery Ventures. The current firm directory states: Jan Deepen General Partner Co-Founder - Zeitgold Co-Founder - SumUp.

Babak Razi serves in Strategy and on the Board of Directors of Ostendo Technologies. Its current board directory also identifies him as a Principal of Third Wave Ventures.

Barak Bussel is a Board Director of Ostendo Technologies. The company's current directory identifies him as a Principal of Third Wave Ventures.

Dale McNeil is published in Ostendo Technologies' current leadership directory with responsibility for system engineering.

Dean Zhao is published in Ostendo Technologies' current leadership directory with responsibility for board director.

Doug Pierce is published in Ostendo Technologies' current leadership directory with responsibility for accounting and financial reporting.

Weilong Tang is published in Ostendo Technologies' current leadership directory with responsibility for semiconductors engineering.

Jason McDowall is published in Ostendo Technologies' current leadership directory with responsibility for research & development.

Chih-li Chuang is published in Ostendo Technologies' current leadership directory with responsibility for product engineering.

David Behzadi is published in Ostendo Technologies' current leadership directory with responsibility for business development & manufacturing and board director.

Hussein S. El-Ghoroury is Founder, Chairman and Chief Executive Officer of Ostendo Technologies. A mobile and telecommunications entrepreneur, he previously served as CTO of IBM Microelectronics, President and CEO of CommQuest Technologies and Senior Vice President of Linkabit. He earned MS and PhD degrees in electrical engineering from Southern Methodist University.

Ostendo Technologies, Inc. is a Carlsbad, California semiconductor and photonics company developing the Quantum Photonic Imager (QPI), a platform that integrates light modulation, micro-LED display technology and processing on a semiconductor device. Its research and reference designs support augmented-reality wearable displays and holographic light-field displays for consumer, enterprise and defense applications. Ostendo combines QPI with optical systems and its Visual Access Operating System, vuOS, to connect wearable visual interfaces to multiple computing platforms. It describes itself as a core technology provider and does not sell Ostendo-branded glasses. Its technical specifications are preliminary and subject to change. Founder Hussein S. El-Ghoroury is Chairman and CEO. Published venture backers include Merkava Holdings and Third Wave Ventures; SEC filings disclose private equity and debt offerings, with offering targets and debt conversions distinguished from new cash raised. A 2023 Veea announcement described a letter of intent to combine businesses, rather than a verified completed merger.

Robert Meese, also known as Bob Meese, is Chief Business Officer of Duolingo, which states he joined in September2016 after working at Google. He holds computer science and economics degrees from the University of Pennsylvania and an MIT MBA. Fundamental Research Labs names Bob Meese as a personal investor in its May2024 seed round, distinct from an investment by Duolingo.

Greg Harper is a games industry executive and personal technology investor. Fundamental Research Labs’ May2024 issuer announcement identifies him as a Supercell executive board member and names him as a personal seed investor. His self-published profile and corresponding portrait confirm the identity. The Supercell position is qualified to the transaction announcement rather than asserted as a new current appointment.

Stephen Lim is a founder and Product Director of Raid Base. Its current official biography describes eight years at Riot Games in project-lead and vice president of research and development roles, including co-creation of Valorant. He is named as a personal investor in Fundamental Research Labs’ May2024 seed round, distinct from any investment by Riot Games or Raid Base.

Mitch Lasky is a former game industry executive and former Benchmark Capital general partner associated with early investments in Riot Games, Snapchat and Discord. His self-published profile identifies him as co-host of the GameCraft podcast and co-owner and board member of LAFC. He is named as a personal investor in Fundamental Research Labs’ May2024 seed round; this is separate from an institutional Benchmark investment.

Jennifer Temel is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Clinical Director of Thoracic Oncology Co-Director, Cancer Outcomes Research and Education Program Professor of Medicine at Harvard Medical School; that title is context, not an executive position at Thyme Care.

Ramy Sedhom is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Assistant Professor, Hematology & Oncology, University of Pennsylvania; that title is context, not an executive position at Thyme Care.

Ravi Parikh is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Associate Professor and Director of the Human-Algorithm Collaboration Lab (HACLab), Emory University; that title is context, not an executive position at Thyme Care.

Robert Young advises Spinogenix on science. A medicinal chemist, he previously led drug-discovery groups at Merck in Montreal and the UK before joining Simon Fraser University. His work has included neuroscience, asthma and arthritis drug development.

Ethan Basch is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Physician-in-Chief of the North Carolina Cancer Hospital, Chief of Oncology and distinguished professor in Medical Oncology and Health Policy & Management at the University of North Carolina; that title is context, not an executive position at Thyme Care.

Joseph Coyle advises Spinogenix on science. His research and academic leadership span developmental neurobiology, glutamate signaling and psychiatric disease, including psychiatry and neuroscience appointments at Harvard and Johns Hopkins.

Lalan Wilfong is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Chief Medical Officer, Navista; that title is context, not an executive position at Thyme Care.

Steven Arnold advises Spinogenix on science and studies Alzheimer’s disease and translational biomarkers. He is a Harvard neurologist based at Massachusetts General Hospital and previously led memory and Alzheimer’s research programs at Penn.

Thomas Leblanc is publicly listed by Thyme Care as Scientific Advisory Board Member. The directory describes their outside affiliation as Associate Professor of Medicine, Duke University School of Medicine; that title is context, not an executive position at Thyme Care.

Jeff Vacirca is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as CEO, New York Cancer & Blood Specialists; that title is context, not an executive position at Thyme Care.

Steven (Steve) Young serves on Spinogenix’s board. The former NFL quarterback co-founded private-equity firm HGGC and the Forever Young Foundation. He is distinct from Cambridge AI researcher and Amadeus venture partner Steve Young.

Alti Rahman is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Chief Strategy and Innovation Officer, American Oncology Network; that title is context, not an executive position at Thyme Care.

Stephen Schleicher is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Medical Oncologist, Tennessee Oncology; that title is context, not an executive position at Thyme Care.

Kathy Giusti is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Co-Founder and Board Director of the MMRF; that title is context, not an executive position at Thyme Care.

Samyukta Mullangi is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as VP Clinical Strategy, OpenEvidence; that title is context, not an executive position at Thyme Care.

Bob Badal is publicly listed by Thyme Care as Advisor. The directory describes their outside affiliation as Co-Founder & Chief Revenue Officer, Strive Health; that title is context, not an executive position at Thyme Care.

Ryan MacDonald is Spinogenix’s chief business officer. His earlier corporate-development and finance roles include Bristol Myers Squibb, Novavax and Pfizer, covering acquisitions, licensing, divestitures and capital markets.

Sasha Damouni Ellis leads investor relations for Spinogenix and is a founding partner of Damouni Group. Her earlier corporate-affairs and investor-relations leadership includes Vir Biotechnology. Her company role is recorded without implying exclusive employment.

Sharron Gargosky leads development at Spinogenix. A biochemist with international drug-development experience, she has overseen regulatory, manufacturing, nonclinical, clinical and medical-affairs work across small molecules, biologics, diagnostics and cellular therapies.

Craig Erickson is Spinogenix’s chief medical adviser and a translational researcher in neurodevelopmental disorders. His work at Cincinnati Children’s includes patient-level measures of brain target engagement and precision approaches to evaluating investigational therapies.

Peter Vanderklish is Spinogenix’s chief science officer. His research concerns synaptic plasticity, dendritic spines and the molecular mechanisms of neurological conditions, including Fragile X syndrome. His graduate training was at UC Irvine.

Puneet Singh is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as CEO, CareBridge; that title is context, not an executive position at Thyme Care. Puneet Singh is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: CEO, Quartet Health; Chief Growth Officer, Anthem Diversified Business Group. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Los Angeles clinical-stage biotechnology company founded by Stella Sarraf in 2016, developing small-molecule therapeutics intended to restore or correct brain synapses. Tazbentetol, formerly SPG302, is being investigated in ALS, Alzheimer’s disease and schizophrenia; SPG601, also named codabakalner, is being developed for Fragile X syndrome. The company’s research spans neurodegenerative, neuropsychiatric and neurodevelopmental conditions. Its candidates remain investigational: orphan designations, Fast Track status and an authorized expanded-access program are distinct from marketing approval. Public research support includes NIH and US Department of Defense grants, separate from equity financing. An SEC filing disclosed a fully sold USD5,199,985 equity offering in 2023; the March2026 filing describes an ongoing offering rather than a completed USD35 million financing.

Alyssa Reisner is publicly listed by Thyme Care as Board Observer. The directory describes their outside affiliation as Lead Director and Investment Principal, CVS Health® Ventures; that title is context, not an executive position at Thyme Care. Alyssa Reisner is a General Partner leading early- and mid-stage investments for CVS Health Ventures’ dedicated corporate fund. She studied at Babson College and has worked across CVS enterprise strategy and digital functions, including transactions in specialty care, nutrition, women’s and behavioral health. Her current manager title is separate from the older Lead Director and Investment Principal wording in Thyme Care’s observer biography.

Vijay Patel is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Managing Partner, CVS Health® Ventures; that title is context, not an executive position at Thyme Care. Vijay Patel is Managing Partner of CVS Health Ventures, overseeing direct venture investing, minority growth equity, limited-partner investments and market development. He previously led enterprise business development and digital-health partnerships after joining CVS’s Boston Digital Innovation Lab in2015, and earlier invested at H.I.G. Growth Partners and Bain Capital. He holds a University of Pennsylvania Management and Technology bachelor’s degree and an MIT Sloan MBA.

James Olsen is publicly listed by Thyme Care as Board Observer. The directory describes their outside affiliation as Founder & Managing Partner, Concord Health Partners; that title is context, not an executive position at Thyme Care.

Bill Frist is publicly listed by Thyme Care as Board Observer. The directory describes their outside affiliation as Co-Founder & Partner, Frist Cressey Ventures; that title is context, not an executive position at Thyme Care. Bill Frist is publicly named in Despierta’s combined advisors and select limited partners roster. The source does not distinguish this individual’s advisory or LP capacity, identify a commitment amount, or supply a substantive biography; its generic image and placeholder biography are excluded. The affiliation is recorded with this explicit limitation. Bill Frist is the physician and former US Senate majority leader identified as William H. Frist in BehaVR’s December 2020 SEC director schedule. The company affiliation is historical and does not imply a personal investment. His own biography confirms his cardiac and heart-lung transplant surgical career and subsequent healthcare investment leadership.

Brenton Fargnoli is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Partner, Lightspeed Venture Partners; that title is context, not an executive position at Thyme Care.

Brian Belsky is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as Managing Director, Concord Health Partners; that title is context, not an executive position at Thyme Care.

Elizabeth Canis is publicly listed by Thyme Care as Board Member. The directory describes their outside affiliation as COO, Wellvana & Executive Advisor, Foresite Capital; that title is context, not an executive position at Thyme Care.

Jesse Waldron is publicly listed by Thyme Care as Chief Financial Officer.

Robin Shah co-founded Thyme Care in2020 and became executive chairman effective September1,2026 after serving as CEO. He focuses on expansion through Thyme Companies, the newly announced parent of the Thyme businesses.

Scott Voigt is publicly listed by Thyme Care as SVP, Product.

Stead Impact Ventures is a Stead family office founded by Jerre Stead in 2023. It invests in early-stage healthcare companies addressing neurodegenerative disorders, mental health and metabolic health, and supports founders with leadership, commercialization, marketing and strategic partnerships. Its published portfolio includes neuroscience diagnostics and therapeutics developers ALZpath, Amydis and Spinogenix, AI ergonomics company Inseer, patient monitoring developer Darroch Medical Solutions and MedWatch Technologies, which combines non-invasive glucose sensing with AI coaching. Venture investments operate alongside the Stead Foundation’s separate philanthropic grants. No externally raised fund closing or fund size was established from the available primary sources.

Ashley Patton is publicly listed by Thyme Care as VP, Thyme Care Oncology Partners.

Etan Raskas is publicly listed by Thyme Care as VP, Business Development and Operations.

Rob Rodkey is publicly listed by Thyme Care as SVP, Engineering.

Nikkayla Page is publicly listed by Thyme Care as VP, Marketing & Communications.

Marcia Macphearson is publicly listed by Thyme Care as Chief Operating Officer.

Michael Markowicz is publicly listed by Thyme Care as Chief Legal Officer.

Jeff Lovesy is publicly listed by Thyme Care as SVP and GM of Commercial Partnerships.

Nicki MacManus is publicly listed by Thyme Care as GM, Clinical Trials.

Alphan Kirayoglu is publicly listed by Thyme Care as SVP, Data Science.

Chris Lau is publicly listed by Thyme Care as VP, Health Economics.

Mark Lombardi is publicly listed by Thyme Care as SVP, Provider Partnerships.

Ahsan Khan is publicly listed by Thyme Care as Deputy General Counsel.

Jessa Kelley is publicly listed by Thyme Care as Chief of Staff.

Joon Sung Park is a computer scientist studying generative AI agents and simulations of human societies. He earned a Stanford computer science PhD in 2025 and is co-founder and CEO of Simile, as identified in his June2026 curriculum vitae. His work includes the 2023 Generative Agents study. Fundamental Research Labs identifies him as a personal participant in its January2024 pre-seed round.

Zachary Weiner, also known as Zack Weiner, co-founded the sports media and entertainment company Overtime and was publicly identified by the company as president. Fundamental Research Labs identifies the Overtime co-founder as a personal participant in its January2024 pre-seed round. This is distinct from the Chase designer and lawyers with similar names; no current executive appointment date is inferred.

Julia Ivanova is publicly listed by Thyme Care as SVP, Growth and Value-Based Partnerships.

Bobby Green is a medical oncologist who co-founded Thyme Care in2020 and remains its president and chief medical officer and a board member. Bobby Green is listed in Thyme Care’s public medical-provider directory as Oncologist. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Julia Frydman is publicly listed by Thyme Care as VP, Clinical Outcomes. Julia Frydman is listed in Thyme Care’s public medical-provider directory as Palliative Care Physician. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Manya Ellenberg is publicly listed by Thyme Care as SVP, People.

Ross Feinstein is publicly listed by Thyme Care as Head of AI Platform.

Brian Dorsey is publicly listed by Thyme Care as SVP, Clinical Innovation and Delivery Design. Brian Dorsey is listed in Thyme Care’s public medical-provider directory as Complex Care Physician. The affiliation is with its clinical-provider network; the site distinguishes Thyme Care LLC’s management/navigation services from clinical services delivered by affiliated provider entities. The exact employing provider entity is not specified.

Head of Engineering at Davidovs Venture Collective. Engineer with founder experience and earlier DoorDash, Cherry Labs and VK work. Builds AI agents, automated workflows, data integrations and the fund platform backend.

Head of Investor Relations and Community at Davidovs Venture Collective, responsible for investor relations and back-office operations. Previously worked with the Davidovs in startup operations, event and community management. Primary personal repost confirms the AI Fund completed its first close.

Venture Partner at Davidovs Venture Collective working across its Seed and AI funds, and active Seed Fund LP and Deal Captain. Own biography describes product work at Meta and earlier Perplexity, Google and MetaArcade experience; prior affiliations are not additional DVC employment roles.

Head of Product at Davidovs Venture Collective, leading product management and analytics operations. Repeat founder with an exit; helped develop Seed Fund automation.

General Partner at Davidovs Venture Collective focused on its AI Fund, and active Seed Fund LP and Deal Captain. Founder of FrontPage, acquired by Microsoft, experienced investor and Academy Award-winning filmmaker.

General Partner at Davidovs Venture Collective focused on its AI Fund. Prior startup experience at IMVU and corporate development, product management and governance experience at Yahoo and Google. Previously a naval officer on a nuclear submarine.

Founder and Managing Partner of Davidovs Venture Collective, focused on investments and portfolio management. Repeat AI founder and investor, co-founder of Cherry Labs and Gagarin Capital, with earlier iTech Capital and MSQRD experience. Personal historical investments and prior firm investments are separate from DVC institutional checks.

Founder and Managing Partner of Davidovs Venture Collective. Former AI startup founder and operator at Humanism.is and Cherry Labs and investor at Gagarin Capital. Leads DVC strategy, investment process, internal products and community.

Davidovs Venture Collective (DVC) is a Silicon Valley venture capital firm founded in2021 by Marina Davidova and Nick Davidov and headquartered in Los Altos Hills, California. It backs early-stage AI businesses led by experienced founders through a community of founders, engineers, researchers and individual investors. Its evergreen rolling Seed Fund targets pre-seed and seed investments, with typical checks of $100,000–$300,000. DVC AI Fund I supports portfolio companies in Series A and B with typical $1million–$3million checks; a completed first close is independently confirmed by a primary firm announcement, while the reported $75million launch figure is not treated here as a verified final close. The current published operating team has eight people, including the founders, general partners Mel Guymon and Charles Ferguson, venture partner Alexey Rybak, and product, community and engineering leaders. Its primary disclosed portfolio includes CopilotKit, Perplexity, Etched, Thinking Machines Lab, Higgsfield, Rhoda AI, Eloquent AI, Boldr and Lovi. The firm is distinct from unrelated businesses using DVC, including Doha and Dallas venture firms, and from The Venture Collective (TVC).

Brad Diephuis is a primary care physician and CEO of Thyme Care, effective September 1, 2026. Previously its president and COO, he joined in2022 as chief business officer after advising the Center for Medicare and Medicaid Innovation. Brad Diephuis is a primary care physician and CEO of Thyme Care, effective September 1, 2026. Previously its president and COO, he joined in2022 as chief business officer after advising the Center for Medicare and Medicaid Innovation.

Nate Brown is publicly listed by Thyme Care as SVP, Market Operations. Nate Brown is publicly listed by Thyme Care as SVP, Market Operations.

Third Wave Ventures is a venture investment firm founded in1996 and headquartered in Beverly Hills, California, with a published office in Beijing. It incubates seed-stage companies in foundational deep technologies, including semiconductors, photonics, clean energy and the Internet of Things. Its committed-capital approach provides sustained funding partnerships to entrepreneurs and brings in selected strategic investors in later rounds. Its own published portfolio names Innovent Systems, acquired by Broadcom; Neven Vision, acquired by Google; Ostendo; and Ingenu. Neven Vision supplies a historical computer-vision connection, while the current explicit firm thesis centers on hardware and deep technology. Babak Razi and Barak Bussel are confirmed firm principals; UCLA also identifies Bussel as a managing partner. Public sources reviewed do not disclose completed firm fund closes or check-size ranges. The firm is distinct from robotics company Third Wave Automation, from other firms using Third Wave in their names, and from separately managed affiliated investment vehicles.

Heidi Spitz is Head of Revenue Operations at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Craig Irwin is Vice President of Sales at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Atai Barkai is Co-Founder and Chief Executive Officer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Alex Clarke is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

David McKay is Head of Forward Deployed Engineering at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Cham Española is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Martha Schumann is Software Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Dustin Clark is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Precious Aprille Plata is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Josh Gordon is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Jerel Velarde is Staff Applied AI Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Mark Fogle is Lead, Partnerships and Integrations at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Benjamin Taylor is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Anmol Baranwal is Technical Writer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Austin Merrick is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Alem Tuzlak is Software Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Lukas Moschitz is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Maxim Zubarev is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position. His own website identifies CopilotKit as a previous client; retain this as a technical collaboration rather than asserting current salaried employment.

Mike Ryan is Principal Architect at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Sam Julien is Director of Product at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Sofía Sánchez-Zárate is Head of Technical Ecosystems at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Eli Berman is Growth Team at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Nathan Tarbert is Community and Developer Relations at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Maximiliano Korp is publicly acknowledged by CopilotKit co-founder and CEO Atai Barkai as a contributor to its team. A precise job title, employment arrangement and appointment date have not been verified; this association does not imply an employee position.

Ran Shem Tov is Founding Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Markus Ecker is Software Engineer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Tyler Slaton is Founding Engineer and Head of Open Source at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Travis Murdock is Head of Go-To-Market at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications.

Jordan Ritter is Chief Technology Officer at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications. He publicly announced joining as CTO in May2026 after previously mentoring and advising its founders. He co-founded Napster.

Uli Barkai is Co-Founder and Head of Growth at CopilotKit, which develops open-source infrastructure for integrating AI agents and generative user interfaces into software applications. He co-founded the company with his brother Atai. The investor portfolio uses the CMO title; published current reporting describes his growth leadership.

Felix Wong is Chief Technology Officer at Fundamental Research Labs. The recruiting firm that placed him identifies his CTO appointment, and his own current profile identifies the company. He previously led engineering for Snap’s My AI and worked on Meta Messenger.

Manuel E. Cortés Rada is publicly affiliated with Fundamental Research Labs on his current self-published professional profile and contributed to its Project Sid multi-agent research. A specific current job title is not publicly disclosed in the retrieved profile.

Peter Y. Wang is a founding scientist at Fundamental Research Labs, formerly Altera.AL, working on AI agents. The company’s 2024 welcome identifies prior Stanford postdoctoral neuroscience research in Karl Deisseroth’s laboratory, a Columbia neuroscience PhD in Richard Axel’s laboratory and a Google X AI residency. His current self-profile retains the Altera affiliation. He is distinct from Anaconda co-founder Peter Wang.

Nico Christie co-founded Fundamental Research Labs, formerly Altera.AL, and created its Shortcut Excel AI product. He was identified as Chief Business Officer at the 2024 launch. His own 2026 announcement says he stepped away from the FRL and Shortcut operating team; he is not represented as a current operating executive.

Andrew Ahn is a co-founder of Fundamental Research Labs, formerly Altera.AL, publicly identified as Chief Science Officer at its 2024 launch. He earned a mathematics PhD at MIT in 2020. His identity matches the mathematician’s Cornell profile, distinct from other people with the same name.

Shuying Luo is a co-founder and the founding CTO of Fundamental Research Labs, formerly Altera.AL. Her current public work includes model training and infrastructure for the Pivot0.5 spreadsheet and finance model. Founding CTO is a historical title; Felix Wong subsequently joined as CTO.

San Francisco Bay Area AI research and product company led by computational neuroscientist Guangyu Robert Yang. Established as Altera.AL in December 2023 following the earlier LyfeGame name, it adopted Fundamental Research Labs in May 2025; it is distinct from Intel’s Altera FPGA semiconductor business. The company develops autonomous and collaborative AI agents, drawing on computational neuroscience and multi-agent learning. Its current Shortcut product is an AI Excel analyst for spreadsheet modelling and analytical workflows. Earlier products and research include the Fairies computer-use assistant and Project Sid, a study of social collaboration among large populations of agents in game environments. Pivot 0.5, announced in 2026, is a specialised spreadsheet and financial reasoning model built through post-training Qwen3.5-27B. Its ambitions for digital humans and self-awareness are research goals rather than evidence of machine consciousness; product benchmark comparisons are company evaluations. Yang previously served on MIT’s computational neuroscience faculty. Publicly identified founders include Shuying Luo, Andrew Ahn and Nico Christie; Christie announced leaving the operating team in 2026. Felix Wong is the later CTO. The company announced a $2 million pre-seed in January 2024, a $9 million seed in May 2024 and a $33 million Series A in August 2025, representing $44 million across those individually disclosed rounds. Its neuroscience connection concerns founder training and AI research, not an approved medical or brain-interface product.

Guangyu Robert Yang is co-founder and CEO of Fundamental Research Labs, formerly Altera.AL. A computational neuroscientist and former MIT faculty member, he leads research and products involving autonomous and collaborative AI agents.

CopilotKit is a Seattle-based AI developer-infrastructure company founded by brothers Atai Barkai and Uli Barkai and operated by Tawkit, Inc. It develops open-source SDKs and enterprise software for embedding AI agents into applications with streaming responses, shared state, tool actions, human review and generative user interfaces. The company created AG-UI, an open agent–user interaction protocol, and provides frontend SDKs, backend integrations, messaging-channel connections and an Enterprise Intelligence platform for persistent agent threads and application data. Its products connect AI-agent frameworks to web, mobile and workplace messaging interfaces. Its AI relevance is software infrastructure and human–agent collaboration; no neurological or medical-device indication is claimed. The company and Glilot’s investment lead announced a $27 million Series A on May5,2026; summaries that divide this total between seed and Series A funding are documented as conflicting disclosures and are not counted again. Public sources name its founders, technology/product leaders, growth team, engineers and technical collaborators; unnamed open-source contributors are not treated as employees.

AimedBio is a South Korean biotechnology company spun out of Samsung Medical Center that develops antibody-based cancer therapies, including antibody-drug conjugates. Its P-ADC platform combines patient-derived data and disease models to identify targets, validate candidates and build precision oncology medicines. Its pipeline includes the FGFR3-targeted ADC AMB302/BHV-1530 for solid tumors including glioblastoma, licensed to Biohaven, and additional ADC and bispecific ADC candidates. The company also develops payload technologies and blood-brain-barrier delivery partnerships; it listed on KOSDAQ in December 2025.

BrickBio is a biotechnology company developing precision biologics with an expanded genetic code and site-specific protein conjugation platform. It incorporates synthetic amino acids into proteins expressed in living cells, allowing selected sites to carry drug payloads, targeting ligands or other functional groups. The platform supports antibody-drug conjugates, multi-payload conjugates, protein therapeutics and targeted delivery approaches for AAV gene therapies, oligonucleotides and nanobodies. BrickBio is developing its own preclinical oncology candidates and works with pharmaceutical partners to engineer therapeutic molecules.

Efinix develops field-programmable gate arrays and embedded computing solutions for energy-efficient AI and other processing at the edge. Its Quantum programmable architecture underpins Trion and Titanium FPGA families used in machine vision, industrial automation, automotive, communications, medical equipment and physical AI. The company pairs its chips with the Efinity design environment and Sapphire RISC-V system-on-chip solutions so developers can implement custom logic, processor systems and AI acceleration on reconfigurable silicon.

Flexcompute develops GPU-native physics simulation software and AI tools that help engineers design aircraft, vehicles, chips and photonic devices. Flow360 models fluid dynamics; Tidy3D simulates electromagnetics and other coupled physics; PhotonForge combines photonic circuit design, simulation and fabrication constraints. GeometryAI automates geometry processing, AutoInsight applies physics-informed AI to aerodynamic design exploration, and FlexAgent lets AI agents operate simulation and design workflows. Its Physics Twins combine validated simulations with AI so teams can evaluate designs and reduce reliance on slow physical prototyping.

Liner develops AI search, academic research and writing tools for students, researchers and professionals. Its search agent provides answers linked to sources, while Liner Scholar supports finding and comparing papers, literature reviews and citation-based academic work. Liner Write turns research into drafts and documents, and the company offers research-agent workflows, APIs and MCP integrations as well as enterprise search technology. Founded in 2015, Liner evolved from a web-highlighting tool into an AI research platform with operations in Seoul and San Francisco.

MangoBoost develops full-stack AI infrastructure built around proprietary data processing units, inference software, servers and distributed storage. Its BoostX DPUs offload networking, storage and security work to free GPUs for AI processing; LLMBoost optimizes distributed language-model inference across heterogeneous accelerators. Alphonso GPU servers and Kesar storage systems combine these capabilities into infrastructure for enterprise AI training, inference and agent workloads. It also develops an AI orchestration platform and end-to-end data center deployment options. Mango Inference is an upcoming service accepting preregistrations, rather than a generally available product.

SiFive designs and licenses customizable processor and system intellectual property based on the open RISC-V instruction-set architecture. Its scalar, vector and matrix CPU cores support AI and machine-learning workloads across datacenters, automotive systems, edge devices, consumer electronics and industrial applications. SiFive also supplies development boards, software tools and security and memory-management IP that help semiconductor companies build differentiated, energy-efficient chips.

WitnessAI develops an enterprise AI security and governance platform for employees, AI models, applications and autonomous agents. It discovers AI usage, observes prompts and responses, enforces identity- and intent-based access policies, controls agent connections to tools and MCP servers, and provides audit trails. Its runtime defenses help prevent sensitive-data leakage, prompt injection, jailbreaks and harmful outputs; the platform also supports AI spending analysis and model routing. Based in Mountain View, California, WitnessAI helps organizations deploy and use AI with security and compliance controls.

Scientific adviser leading the scientific advisory board for BrickBio’s expanded genetic code and bioconjugation platform.

Leads WitnessAI engineering; previously led engineering and product at LevelBlue/AT&T Cybersecurity and product at AlienVault.

Leads AI research at WitnessAI on enterprise model and agent safety, prompt analysis and production AI systems; previously at SpreeAI and Valify.

Co-founder and General Partner at Ballistic Ventures; previously led AlienVault and AT&T Cybersecurity. Ballistic Ventures affiliation: Barmak Meftah is a co-founder and General Partner at Ballistic Ventures. He previously led AT&T Cybersecurity following its acquisition of AlienVault, which he had led as CEO. Earlier responsibilities include enterprise security at HP, product leadership at Fortify Software and product management at Oracle. He advises cybersecurity founders on company operations, product development and team-building; existing WitnessAI roles remain intact.

Semiconductor industry executive and former Altera Chief Revenue Officer and Movella CEO. Efinix appointed him as a strategic adviser in February 2026 to support go-to-market strategy, organizational scaling and revenue growth.

Co-founder and Chief Operating Officer of Liner.

Antibody-therapeutics researcher and former head of antibody development at AimedBio; trained in convergent medical science at Sungkyunkwan University.

Chief Commercial Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Christopher Norris has served as a member of our board of directors since May 2018, as a member of our Audit Committee since November 2018, and as Chairman of our Audit Committee from November 2018 to 2026. Mr. Norris has served as an Executive Director at Santa Clara University since November 2018, where he is also adjunct faculty, and the founding Executive Director of the Ciocca Center for Innovation and Entrepreneurship. Previously, Mr. Norris served as President, Chief Executive Officer and a board member of Alta Devices, Inc., and as a Venture Partner at BlueRun Ventures. Earlier, he served as President, Chief Executive Officer and a board member of MicroDisplay Corporation and spent 17 years at Cypress Semiconductor Corporation. Mr. Norris is the founder of Aurinko Group, an executive consulting firm. Mr. Norris has a Bachelor of Science degree in Electrical Engineering from the University of Idaho and a Master of Science degree in Computer Engineering from Santa Clara University.

Oncologist and clinical drug-development expert whose work includes pancreatic-cancer therapeutics and clinical investigations.

Enterprise product executive with experience at Zscaler, Symantec, NeXT/Apple and Sun.

Neurosurgeon and professor at Samsung Medical Center and Sungkyunkwan University specializing in brain tumors and CNS diseases; founder of AimedBio.

Chief Technology Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Chief AI Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Pharmacist and Korean attorney whose career includes clinical research at AstraZeneca and Servier and legal leadership at MedPacto.

Product designer at Liner working on AI search and research experiences.

Chief Executive Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Drug-development CMC specialist with experience at Bridge Biotherapeutics, Iljin Inopharm, SK Biopharmaceuticals and LG Life Sciences; organic chemistry PhD from Hanyang University.

Distinguished technologist on Flexcompute’s current published team; IEEE Fellow with a PhD in electrical engineering from the University of Michigan.

Co-founder and CEO of BrickBio, developing precision biologics through protein engineering.

Business and legal executive whose career includes Samsung Bioepis, GSK and Kim & Chang; JD from George Washington University.

Chief Operating Officer and Chief Financial Officer of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

General Partner at GV focused on enterprise software, analytics and cybersecurity. Current GV source qualification: Karim Faris is published by GV as General Partner. A general partner investing in enterprise software and related technology. Existing profile emphasizes analytics and cybersecurity; current own GV directory and biography establish continued affiliation.

Neurosurgery professor at the National Cancer Center with academic and medical-governance experience.

Leslie Leung has served as a member of our board of directors since May 2024. He has served as a Senior Vice President at Chow Tai Fook Enterprises Limited (“CTFE”), a Hong Kong-based diversified investment holding company since February 2017. Prior to CTFE, Mr. Leung was a Strategic Investment Manager at Alibaba Group Holding Limited, and worked as an investment banker at Rothschild & Co. He served on the board of directors of Spinifex OWF Holdings Pty Ltd, Spinifex Offshore Wind Farm Pty Ltd, and other companies affiliated with CTFE, and as an alternate director for Pioneer Sail Holdings Pty Limited, Pioneer Sail Australia Pty Limited, Alinta Energy Pty Limited, and Latrobe Valley Power (Holdings) Pty Ltd. Mr. Leung holds a Bachelor of Commerce degree from the University of Auckland (New Zealand), and is a CFA charterholder and a Fellow of CPA Australia (FCPA).

Co-founded Liner and leads its AI search and research business; also publicly known as Luke Kim and Jinu Kim.

Leads financial strategy and operations at WitnessAI; experienced adviser to venture-backed companies.

Research and operations professional with experience at Samsung Medical Center and Ajou University; biology degrees from Yonsei University.

Mohd Rashdan Abdul Razak has served as a member of our board of directors since December 2023. Mr. Razak currently serives as Head of the Special Investment Unit in the Government Investment Companies Division of the Ministry of Finance, Malaysia. Mr. Razak began his career as a Research and Development Engineer in Japan and later in Malaysia before he joined the Malaysian Public Service Department as an Assistant Secretary in the Electricity Supply Division of the Ministry of Energy, Green Technology and Water. He has also served as the Senior Assistant Secretary in the International Relations Division of the Ministry of Higher Education and subsequently assigned to the Development Division in the same Ministry. Mr. Razak serves on the board of directors of Johor Port Berhad, Innocorp Ventures Sdn Bhd, Inno Bio Ventures Sdn Bhd and iGene Sdn Bhd. He holds a Bachelor of Electrical and Electronic Engineering from Ibaraki University (Japan), an MBA from University Malaya (Malaysia), a Diploma in Public Administration from Institut Tadbiran Awam Negara (INTAN), and a Certificate in International Studies from University of Bath (United Kingdom).

Certified public accountant with experience at NICE Investors Service and Samil PwC.

Oncologist researching lung and head-and-neck cancers and targeted therapies.

Former head of R&D at AimedBio and principal scientist at Samsung Medical Center; trained in life sciences at Korea University.

Oncology drug-development executive with experience spanning targeted therapies and biotechnology R&D.

Product data analyst collaborating with product, engineering and design teams at Liner.

Retired United States Army general, former NSA director and commander of U.S. Cyber Command; founding director of Vanderbilt’s Institute of National Security. Ballistic Ventures affiliation: Retired General Paul M. Nakasone is an external adviser to Ballistic Ventures. He served for nearly four decades in the US Army and ended his military career as director of the National Security Agency and commander of US Cyber Command. His published professional profile includes founding leadership of Vanderbilt’s Institute for National Defense and Global Security and OpenAI board service. He is the same Paul M. Nakasone already profiled with WitnessAI; existing affiliations and financial references are preserved.

Distinguished technologist on Flexcompute’s current published team; National Academy of Engineering member with a PhD in aeronautics and astronautics from Stanford University.

Co-founder and distinguished technologist at Flexcompute. The company’s founder story describes him as an MIT engineering professor; the team page lists a Stanford PhD in computational and mathematical engineering.

Biopharmaceutical business-development and licensing specialist with experience at Arena Pharmaceuticals and Ignyta.

Antibody-drug-conjugate researcher and former ImmunoGen chemistry and biochemistry executive.

Richard Sevcik has served as a member of our board of directors since May 2018, as a member of our Compensation Committee since November 2018, and as the sole member and de facto Chairman of our Compensation Committee since February 2021. Mr. Sevcik spent nearly a decade as Executive Vice President at Xilinx, Inc. After Xilinx, Mr. Sevcik founded Sevcik Consulting, which provides consulting services to semiconductor companies. Mr. Sevcik has served as a member of boards of directors and committees of publicly-traded companies, including Xilinx Alpha & Omega Semiconductors (Audit, Compensation and Governance committees) and Liquidmetal Technologies (Compensation committee). Mr. Sevcik has a Bachelor of Science degree in Engineering with a major in Physics from the University of Illinois and a Master of Science degree in Computer Science Engineering from Northwestern University.

Security and compliance executive who led product or marketing at Palo Alto Networks, Google, Symantec, ArcSight and Exabeam.

Neuro-oncologist at Northwestern University whose work helped establish temozolomide with radiotherapy and tumor treating fields for glioblastoma.

Co-founder and General Partner at Ballistic Ventures, formerly a founder and CTO at Fortify Software and AlienVault. Ballistic Ventures affiliation: Roger Thornton is a co-founder and General Partner at Ballistic Ventures. He previously helped build Fortify Software and AlienVault as a founder and technology leader. His career spans cybersecurity product development, company formation, mentoring and investment support. His existing WitnessAI affiliation is retained without inferring a separate personal investment.

Biopharmaceutical research and business-development specialist whose career includes Tanabe Research Laboratories and Biogen-Idec.

Oncologist researching lung cancer, clinical-genomic data and immunotherapy-response prediction.

Co-founder and distinguished technologist at Flexcompute, a researcher in photonics and computational electromagnetics. The company team page lists a PhD in physics from MIT and National Academy of Engineering membership.

Leads WitnessAI marketing; previously held marketing leadership roles at Imperva and Exabeam.

Biotechnology business-development director trained in health sciences and technology at Sungkyunkwan University and biomolecular sciences at the University of Michigan.

Hospital administration executive whose career includes Cheil General Hospital and Bundang CHA Medical Center.

Taraec Hussein has served as a member of our board of directors since February 2026. Mr. Hussein is an investment professional focused on venture capital and private equity across Southeast Asia. He has served as Senior Principal of Jelawang Capital Sdn. Bhd. since March 2025. Prior to joining Jelawang, he was Vice President of Gobi Mavcap Management (Malaysia) Sdn. Bhd. from August 2017 to August 2023. Mr. Hussein began his career in investment banking, where he focused on equity capital markets, including initial public offering pricing, rights issues and secondary placements, before transitioning to venture capital. He currently serves on the board of directors of Axiata Digital Innovation Fund Sdn Bhd and Intres Capital Partners Sdn Bhd. Mr. Hussein holds a Bachelor of Arts degree in Accounting and Finance from the University of Manchester (United Kingdom).

Leads global sales and go-to-market strategy at WitnessAI; previously CRO at Red Canary and Recorded Future.

Vice President of Business Development of MangoBoost, which develops DPUs, inference software and full-stack AI infrastructure. Listed on its current official executive team.

Former Financial Supervisory Service director general and economics graduate of Yonsei University.

Co-founder and President of Flexcompute. Oversees a company building GPU-native physics solvers and AI engineering tools including automotive aerodynamic optimization.

Medicinal-chemistry and drug-development executive with experience at Standigm, Therapex and CrystalGenomics; chemistry PhD from the University of Pittsburgh.

Preclinical-development scientist with life-science undergraduate and graduate degrees from KAIST.

Pathologist specializing in toxicologic pathology and preclinical development.

Pathologist researching anticancer biomarkers and diagnostic methods.

Frontend engineer at Liner working on its search experience.

Co-founder and CEO of Flexcompute, a GPU-native physics simulation and engineering AI company. His company story describes founding the business with Qiqi Wang and Shanhui Fan.

Merkava Holdings is the private investment arm of the Philip E. Werthman Trust, founded and led by physician, entrepreneur and investor Philip Werthman. It backs early and mid-stage companies and platform technologies in life sciences, biotechnology, pharmaceuticals, software, high technology, wireless communications, semiconductors, aerospace, security and defense. It also participates in real estate development and financing. The firm supports companies through business development, international financing relationships and global distribution networks. Its published investment portfolio includes Amydis, which develops investigational retinal molecular tracers for neurodegenerative diseases, and Spinogenix, a neuroscience therapeutics developer. The website separately categorizes investment portfolio companies, advisory or board relationships, and product distribution; an advisory appointment alone does not establish an investment. No named investment fund, closed fund size, assets under management, founding year or legal incorporation jurisdiction has been verified.

Korsana Biosciences develops precision-engineered antibody therapies for neurodegenerative diseases. Its Therapeutic Targeting (THETA) platform, developed with Paragon Therapeutics, combines transferrin-receptor and Fc engineering to transport medicines across the blood-brain barrier. Lead investigational candidate KRSA-028 is a shuttled anti-amyloid-beta antibody designed for Alzheimer’s disease, with initial clinical data planned for 2027. Korsana completed its merger with Cyclerion Therapeutics in September 2026 and now operates as the public company under the Korsana name.

Nura Bio develops neuroprotective small-molecule medicines intended to halt axon degeneration and preserve neuronal function in neurological diseases. Its pipeline targets SARM1, an injury-activated enzyme that depletes NAD and triggers axon destruction, alongside research into neuron–glia immune regulation. Oral, brain-penetrant SARM1 inhibitor NB-4746 is in a Phase 1b/2a ALS study, while next-generation covalent allosteric inhibitor NB-9402 has entered first-in-human testing. The company combines structural biology, cellular and animal disease models, imaging and biomarker development to advance investigational therapies.

Aarif is the chief scientific officer, providing scientific and strategic leadership across the company’s platform and therapeutic pipeline.

Biotechnology investor at Samsara BioCapital with earlier drug-development experience at Revolution Medicines and bluebird bio. Abe Bassan is listed by Samsara BioCapital as Partner. Abraham Bassan joined at the 2017 fund launch after program-biology leadership at Revolution Medicines and drug-development work at bluebird bio.

Beth Grous is the chief people officer at Generate:Biomedicines.

Daria Hazuda, Ph.D., serves as Senior Vice President, Discovery Strategy at Generate:Biomedicines, leading the research team in identifying and prioritizing the best applications of The Generate Platform in vaccines and infectious diseases.

Dinesh is senior vice president, head of clinical drug development at Generate:Biomedicines and has responsibility for all aspects of clinical development and Investigational New Drug (IND) submissions, across immunology and oncology therapeutic areas.

Biologics manufacturing and technical-operations executive with prior experience at Zenas, Voyager, TESARO/GSK and Shire.

Gevorg Grigoryan, PhD, is co-founder & Chief Technology Officer at Generate:Biomedicines, where he leads development of the Generate Platform—an integrated system for generating new drugs on demand across diverse biologic modalities.

Biopharmaceutical finance executive and director with prior CFO experience at Pardes, Imbria and Kura Oncology.

Jason Silvers is President & Chief Financial Officer of Generate:Biomedicines, overseeing the company’s financial organization and supporting enterprise scale through capital formation and strategic transactions.

Neurologist and clinical-development leader with previous experience at Amylyx, Biogen, Amgen and Annexon.

Laurie is the chief medical officer (CMO) of the immunology and inflammation (I&I) portfolio and is responsible for providing strategic, scientific and operational leadership for the company’s late-stage clinical development programs in I&I.

Neuroscientist at the OHSU Vollum Institute researching axon degeneration and neuron-glia signaling; his laboratory identified SARM1 as a driver of axon destruction.

Biotechnology physician-scientist and company builder with experience at Revolution Medicines, Third Rock Ventures and several early-stage companies.

Sahm is head of Business Development, Strategy, and Program and Alliance Management at Generate:Biomedicines.

Physician-scientist and neuroscience drug-development executive with experience at ImmunoBrain, Roche, Bristol-Myers Squibb, Lilly and Amgen.

Biotechnology business-development executive formerly with Aro Biotherapeutics, Roivant and Celgene.

Sean is the Chief Legal Officer and General Counsel for Generate:Biomedicines, overseeing all legal and compliance matters.

Biotechnology research leader and founding scientist at Nura Bio, with earlier drug-discovery experience at Amgen and NGM Biopharmaceuticals.

Biochemist at UT Southwestern researching molecular regulation and involved in the creation of biotechnology companies including Tularik and Peloton.

Biotechnology investor and company builder at The Column Group, with previous research experience at KAI Pharmaceuticals.

Cionic develops wearable neurotechnology to help people with neurological mobility impairments walk. Its Neural Sleeve combines motion and muscle sensors, adaptive AI and functional electrical stimulation in a garment that analyzes movement and adjusts muscle stimulation in real time. A companion app and mobility specialists support personalized training. The company serves people with conditions such as multiple sclerosis, stroke and cerebral palsy and develops research tools for clinicians studying movement.

Delos Data develops interconnect software, systems and silicon for AI inference infrastructure. Its Nonstop AI architecture connects compute, memory and storage across heterogeneous accelerators, servers and clusters to reduce data-transfer bottlenecks and keep workloads running through failures. Its products include AI cluster and server architectures and a universal data-interface chip, aimed at supporting large-scale agentic AI workloads with lower latency, higher bandwidth and more resilient data movement.

Enable Ventures invests in early-stage technology companies that improve accessibility, employment and independence for people with disabilities while pursuing market-rate returns. Its focus includes AI and machine learning, workplace tools, digital health, skills training and assistive hardware, with disability-inclusive design as an investment thesis. Founded by Regina “Gina” Kline, Enable operates within the Sorenson Impact platform; its manager is Enable Ventures Management, LLC.

Alain Gravel serves as Vice President, Engineering at Delos Data.

Annie Winterhall is the Head of Clinical Operations at Cartography.

Neurologist and founder of the MS Center for Innovations in Care.

Bing Gordon is published by Matter Venture Partners as Advisor.

Medtech and digital-health commercial leader; formerly held leadership roles at Resmed and Aria Health.

Carl June is a physician scientist and the Richard W.

Early-stage investor with a neuroscience PhD from the University of Utah.

Chelsea Dvorak is published by Matter Venture Partners as Head of Operations.

Chester Wong is Senior Vice President, Head of Business Development at Cartography.

Colin Born serves as Vice President, Finance & Strategy at Delos Data.

Dan Daly serves as Chief Technology Officer & Co-founder at Delos Data.

Dan Rock is Chief Scientific Officer at Cartography, where he leads scientific operations and aligns strategy with the company’s mission.

David Kugler is Vice President of Research & Development at Cartography and is the Global Asset Lead for Cartography’s lead program CBI-1214.

Ed Doe serves as Chief Executive Officer & Co-founder at Delos Data.

Investor with a background in disability public policy, accessible product strategy and business.

Neurologist specializing in neuroimmunology and multiple sclerosis.

Erin Daruszka is our fractional Head of People focused on helping us be an amazing place for people to work and develop.

Hillary Sherpa is published by Matter Venture Partners as Executive Admin, Managing Partner.

Cartography Biosciences co-founder; the company identifies Chang as one of the scientists who initiated its single-cell antigen discovery approach.

Ivy Qiu is published by Matter Venture Partners as Europe Representative.

Janine Schuurman, PhD, is a scientist, inventor, and biotech leader whose career centers around the antibody molecule as a biological source of inspiration and therapeutic modality.

Technology entrepreneur who founded Cionic in 2018 to develop adaptive wearable mobility assistance inspired by his daughter’s cerebral palsy.

Impact investor and business founder whose Sorenson Impact platform supports Enable Ventures.

Kevin Parker is the CEO and co-founder of Cartography Biosciences.